Wesana Health reports positive treatment results in combining traditional antidepressants with psilocybin-based therapy.
Articles
Awakn Life Sciences Announces Closing of Private Placement
Awakn Life Sciences announces closing a a CAD $3.25 million private placement, with units priced at $1.60 along with a half-warrant with an exercise price of $2.20.
Red Light Holland Successfully Imports Psilocybin iMicrodose Packs into St. Vincent and the Grenadines Under a First-Ever Authorized Import Approval Process by the Country's Bureau of Standards and the Ministry of Health
Red Light Holland announces the first-ever import of psilocybin mushrooms into St. Vincent and the Grenadines.
Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments
Awaken receives regulatory approval to begin ketamine-based therapies in its flagship London mental health clinic.
MINDCURE Provides Update on Strategic Review
MINDCURE announces the completion of its strategic review and new cost saving measures.
Novamind to Host MindMed Phase IIb Trial for LSD and Anxiety
Novamind announces it will most MindMed's Phase IIb clinical trial of LSD-based therapy for generalized anxiety disorder (GAD).
Ketamine Wellness Centers (KWC) Announces Grand Opening of Reno Clinic
Ketamine Wellness Centers, a subsidiary of Delic Holdings, announces the grand opening of its 13th ketamine clinic.
Brain Injury Awareness Month: New Hope With Psychedelic Medicine
Thanks to the advance of psychedelic medicine, "brain injury awareness" is about more than highlighting a problem. It's also about new hope for sufferers.
Enveric Biosciences Announces Publication of Four Patent Applications for Psychedelic-Inspired Drug Candidates
Enveric Bioscience announces the publishing of four PCT applications by the World Intellectual Property Organization.
Numinus Expands Natural Psychedelic Research with New Biosecurity License
Numinus announces that its Numinus Bioscience research lab has been approved for a Containment Level 2 (CL2) license from Health Canada.
Wesana Health Announces Positive Feedback From Pre-IND Meeting With FDA on SANA-013
Wesana Health reports positive feedback from FDA on pre-IND meeting regarding development of SANA -013 and is anticipating commencing a clinical trial in Q4 2022.
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
Bright Minds Biosciences announced the successful completion of a 28-day toxicology study for BMB-101.
Red Light Holland and Advocacy Group Psychedelic Medicine Alliance Washington Celebrate the Success of their Collaboration as Washington Legislature Funds Psilocybin Wellness Workgroup
Red Light Holland applauds the decision of Washington State's government to provide $200,000 in funding for psychedelics research.
How Capital Markets Are Fueling Psychedelic Medicine Growth
The psychedelic medicine industry is growing. There was a wave of new psychedelic firms going public, with big names like MindMed and Atai Life Sciences listing on major stock exchanges like the NASDAQ, and increased acceptance of psychedelics by institutional investors.
Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets
Small Pharma announces two more planned clinical trials for 2022 from its pipeline of DMT-based drug candidates.